Outbreaks don’t wait, neither can your platform. Castor powers infectious disease research from peer-reviewed seroprevalence surveillance to large-scale Phase III vaccine trials, with the global reach your program needs from protocol to first patient in.
In an outbreak, time matters. Waiting weeks or months for platform configuration, validation, and site training is not an option. Infectious disease sponsors and global health organizations need a platform that does not require infrastructure to stand up before a study can go live.
Infectious disease studies often run in regions with limited digital infrastructure, variable internet connectivity, and sites that have never used a sophisticated EDC system. The platform must be accessible to a field investigator in a low-resource setting as easily as to a researcher at a major academic medical center.
Adaptive designs, common in outbreak response and vaccine research, require the ability to modify treatment arms, enrollment criteria, and data collection workflows mid-study without triggering a full re-validation cycle.
A study running in 52 countries requires 52-country regulatory compliance, multiple languages, and the ability to manage data standards across jurisdictions, all in one platform instance.
Infectious disease is the only therapeutic area where the pace of the science is dictated by the pathogen, not the sponsor’s development timeline. Outbreak response studies need to be live quickly. Adaptive trial designs need to be modified in real time. Global cohorts need to be enrolled across dozens of countries with minimal site infrastructure. Standard enterprise EDC platforms, with 12-to-16-week deployment cycles and rigid configuration workflows, are structurally incompatible with outbreak response research.
From outbreak activation to Phase III vaccine trials, Castor is designed for the speed, scale, and compliance that infectious disease research demands.
Castor’s SaaS architecture means there is no infrastructure to stand up. Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. The COVID-RED study shows what this enables at scale: a fully remote, decentralized infectious disease study run by Julius Clinical on Castor, recruiting at high volume in a tight window.
The PRECISE study tracked SARS-CoV-2 seroprevalence in healthcare workers across multiple sites in Ireland, enrolling 19,216 participants and capturing 496,174 data points on Castor via ePRO. It is published, peer-reviewed evidence that Castor handles large-scale population surveillance and epidemiological cohort management. For your program, it is proof Castor stands up to the scrutiny of the scientific record.
Source: McGrath J et al., Frontiers in Medicine, 2023 (PMID 36778745)
Castor’s platform supports 15-20 languages, enabling site-level data entry and patient-facing workflows in the local language across study countries, without per-country software builds or separate regional instances. 24/7 multilingual patient support is available in 15-20 languages, with SMS and WhatsApp reminders to maintain engagement across geographically dispersed and resource-limited cohorts. For trials running in China, Castor also supports native WeChat eCOA, so participants complete assessments in an app they already use every day.
Castor’s no-code builder allows for real-time protocol amendments without taking the database offline, an essential capability for adaptive Phase II/III infectious disease studies. Treatment arms, dosing regimens, and enrollment criteria can be modified mid-study as real-world data accumulates, without requiring a full platform re-validation cycle. For outbreak response programs where the pathogen itself can change the protocol, this is a structural requirement that legacy platforms cannot meet.
For infectious disease studies where patients cannot travel to sites, due to quarantine, geography, or the nature of the illness, Castor’s decentralized clinical trial (DCT) toolkit supports remote eConsent, ePRO, telemedicine visit coordination, and remote monitoring. The COVID-RED study is the proof point: Julius Clinical ran a fully off-site infectious disease study on Castor using eConsent, DCT, and MedTech integration, without a single patient needing to attend a clinical facility. In a blinded decentralized screening study, Castor reached greater than 98% screener completion and 90.5% survey completion. These are recent best-case figures, not a platform guarantee.
Full regulatory compliance across all jurisdictions: FDA 21 CFR Part 11, ICH E6 (R2/R3), EU Annex 11, HIPAA, GDPR, ISO 27001, and GCP, with multi-region hosting that keeps health data within borders when required by national health authorities. Castor implements controls to support data sovereignty: the system prevents accidental or deliberate hosting outside the designated area through regional isolation, ensuring medical research data is stored exclusively in the country chosen by the global health organization. Castor offers local data hosting in regions including Australia, helping global sponsors meet data-residency requirements. For WHO-affiliated programs, national health authority studies, and multi-country research with cross-border data flow restrictions, this is a structural necessity, not an add-on. Castor’s platform maintains greater than 99.9% historic mean uptime and has captured 830 million+ data points across studies in 160+ countries, providing the reliability and audit trail depth that emergency and outbreak response programs require.
Data points captured on Castor across studies in 160+ countries, with greater than 99.9% historic mean uptime, including the world’s largest infectious disease programs during active public health emergencies.
Castor powered the PRECISE study, a peer-reviewed, multi-center SARS-CoV-2 seroprevalence study in healthcare workers across Ireland. It enrolled 19,216 participants and captured 496,174 data points via ePRO, published in the scientific literature. This is the proof that matters most: Castor handling large-scale population surveillance and epidemiological cohort management under the scrutiny of peer review.
Published in Frontiers in Medicine, McGrath J et al., 2023 (PMID 36778745).
The WHO Solidarity trial, one of the largest global trials in history, ran on Castor at its stated scale. Castor delivered adaptive medication allocation, rapid site activation, and real-time data collection across 52 countries during an active global health emergency, with six-language support throughout. For your program, that is evidence Castor can handle multi-country activation and remote enrollment at the volume an outbreak demands.
Julius Clinical used Castor to run a fully remote, decentralized study in an infectious disease context, recruiting 17,824 patients in 15 weeks in early 2022. Patients were screened, consented, and monitored via Castor entirely off-site, demonstrating Castor’s DCT capability at high-volume, outbreak-relevant scale. For sponsors facing dispersed or quarantined populations, this is proof that remote enrollment at volume and mid-study amendments without revalidation work in practice.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
SaaS deployment with no infrastructure to provision, plus adaptive design support that lets treatment arms, dosing, and enrollment criteria change mid-study without a full re-validation cycle.
Peer-reviewed and WHO-scale evidence across 600 sites in 52 countries, with six-language data capture during an active public health emergency and support for 15-20 languages in resource-limited settings.
Remote eConsent, BYOD ePRO, and telemedicine coordination, backed by multi-region hosting that keeps data within borders when national health authorities require it.
Castor is a cloud-based clinical trial platform that researchers and global health organizations use to run infectious disease studies at outbreak speed and global scale. There is no infrastructure to stand up, so low-to-medium complexity studies typically move from kickoff to user acceptance testing in 4 to 8 weeks. The same platform powered the peer-reviewed PRECISE seroprevalence study in Irish healthcare workers (19,216 participants), the WHO Solidarity trial at 15,000+ participants across 600 sites in 52 countries, and the COVID-RED study, a fully decentralized, remote infectious disease study run by Julius Clinical.
Castor’s SaaS platform requires no infrastructure deployment. Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. The COVID-RED study demonstrates what this enables at scale: Julius Clinical recruited 17,824 patients in 15 weeks (February 2022), entirely via decentralized remote methods on Castor.
Yes. The peer-reviewed PRECISE study tracked SARS-CoV-2 seroprevalence in healthcare workers across multiple sites in Ireland, enrolling 19,216 participants and capturing 496,174 data points on Castor (McGrath J et al., Frontiers in Medicine, 2023, PMID 36778745). The WHO Solidarity trial, one of the largest clinical trials ever conducted, also ran on Castor at a stated scale of 15,000+ participants across 600 sites in 52 countries. For your program, that scale translates into multi-country activation and remote enrollment at volume on the same platform.
Yes. Castor supports protocol amendments and adaptive design changes mid-study, including modifications to treatment arms, enrollment criteria, and data collection workflows, without requiring a full platform re-validation cycle. This is critical for outbreak response studies where the protocol must evolve as real-world data accumulates.
Yes. Castor’s decentralized clinical trial (DCT) toolkit supports remote eConsent, BYOD ePRO, and telemedicine visit coordination, enabling patients to participate from home without visiting a site. In the COVID-RED study, Julius Clinical conducted all consent and monitoring remotely on Castor. In a blinded decentralized screening study, Castor reached greater than 98% screener completion and 90.5% survey completion. These are recent best-case figures, not a platform guarantee.
Castor offers multi-region hosting that keeps health data within borders when required by national health authorities. The platform implements regional isolation controls that prevent accidental or deliberate hosting outside the designated area, so medical research data is stored exclusively in the country chosen by the sponsor or global health organization. Castor maintains full regulatory compliance across jurisdictions, including FDA 21 CFR Part 11, ICH E6 (R2/R3), EU Annex 11, HIPAA, GDPR, ISO 27001, and GCP. For WHO-affiliated programs and multi-country research with cross-border data flow restrictions, this is a structural part of the platform.
Castor supports 15-20 languages, enabling site-level data entry and patient-facing workflows in the local language across study countries without per-country software builds or separate regional instances. The WHO Solidarity trial used six-language data capture across 600 sites in 52 countries. For dispersed cohorts, 24/7 multilingual patient support is available in 15-20 languages, with SMS and WhatsApp reminders to maintain engagement in low-resource settings.
